|
|
|
|
|
|
Sponsored by: |
Chinese University of Hong Kong |
Information provided by: | Chinese University of Hong Kong |
ClinicalTrials.gov Identifier: | NCT00164801 |
The effect of baclofen (GABAB agonist), diltiazem (muscle relaxant) and placebo will be compared in a double-blinded randomized study for the treatment of NCCP. Cerebral cortical, brainstem and spinal evoked potentials before and after treatment will be evaluated. Results of this study will shed lights on pathogenesis and treatment of NCCP in Chinese.We hypothesize that Baclofen alleviates visceral hyperalgesia in NCCP patients by suppressing afferent sensory pathway.
Condition | Intervention |
Non-Cardiac Chest Pain |
Drug: Baclofen, Diltiazem |
MedlinePlus related topics: | Chest Pain |
Drug Information available for: | Diltiazem Verapamil Dexverapamil Diltiazem hydrochloride Diltiazem malate Verapamil hydrochloride Baclofen |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety Study |
Official Title: | Is Visceral Hyperalgesia the Culprit of Noncardiac Chest Pain in Chinese? Part 2: Effect of GABAB Agonist on Visceral Hyperalgesia in NCCP Patients |
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Study ID Numbers: | NPB study |
First Received: | September 9, 2005 |
Last Updated: | March 25, 2008 |
ClinicalTrials.gov Identifier: | NCT00164801 |
Health Authority: | Hong Kong: Department of Health |
|
|
|